CMB International Capital, a private equity unit of China Merchants Bank, has led a $100 million Series B round for US and China-based biopharmaceutical developer Apollomics.
OrbiMed Asia also participated along with China Renaissance K2 Ventures, Guangdong United Investment, Junson Capital, Panlin Capital, and South China Venture Capital. The fresh capital will be used to...
Ascendent Capital Partners has joined Xuan Ruiguo, the chairman and founder of Hong Kong-listed industrial control systems maker China Automation Group, in a take-private offer that values the company at HK$1.5 billion ($197 million).
Australian investment firm Leap Capital has raised A$50 million ($34 million) for a venture debt fund that will target established, revenue-generating companies locally.
Hansoh Pharmaceutical Group, a Chinese drug developer that counts Hillhouse Capital and Boyu Capital among its investors, has raised HK$7.86 billion ($1 billion) through a Hong Kong IPO.
Fidelity International has announced plans to spin-out its proprietary investment arm Eight Roads within the year pending regulatory and shareholder approvals.